Atlas Trials

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Clinical trial NCT03237780 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03237780
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial CarcinomaLocally Advanced Urethral Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial CarcinomaMetastatic Urethral Urothelial CarcinomaRecurrent Bladder Urothelial CarcinomaRecurrent Renal Pelvis Urothelial CarcinomaRecurrent Ureter Urothelial CarcinomaRecurrent Urethral Urothelial Carcinoma
Start date
2018-07-20
Primary completion
2027-06-30
Enrollment
72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.